Literature DB >> 18710212

Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.

S Kashif Sadiq1, David Wright, Simon J Watson, Stefan J Zasada, Ileana Stoica, Peter V Coveney.   

Abstract

The successful application of high throughput molecular simulations to determine biochemical properties would be of great importance to the biomedical community if such simulations could be turned around in a clinically relevant timescale. An important example is the determination of antiretroviral inhibitor efficacy against varying strains of HIV through calculation of drug-protein binding affinities. We describe the Binding Affinity Calculator (BAC), a tool for the automated calculation of HIV-1 protease-ligand binding affinities. The tool employs fully atomistic molecular simulations alongside the well established molecular mechanics Poisson-Boltzmann solvent accessible surface area (MMPBSA) free energy methodology to enable the calculation of the binding free energy of several ligand-protease complexes, including all nine FDA approved inhibitors of HIV-1 protease and seven of the natural substrates cleaved by the protease. This enables the efficacy of these inhibitors to be ranked across several mutant strains of the protease relative to the wildtype. BAC is a tool that utilizes the power provided by a computational grid to automate all of the stages required to compute free energies of binding: model preparation, equilibration, simulation, postprocessing, and data-marshaling around the generally widely distributed compute resources utilized. Such automation enables the molecular dynamics methodology to be used in a high throughput manner not achievable by manual methods. This paper describes the architecture and workflow management of BAC and the function of each of its components. Given adequate compute resources, BAC can yield quantitative information regarding drug resistance at the molecular level within 96 h. Such a timescale is of direct clinical relevance and can assist in decision support for the assessment of patient-specific optimal drug treatment and the subsequent response to therapy for any given genotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710212     DOI: 10.1021/ci8000937

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  17 in total

1.  The importance of protonation and tautomerization in relative binding affinity prediction: a comparison of AMBER TI and Schrödinger FEP.

Authors:  Yuan Hu; Brad Sherborne; Tai-Sung Lee; David A Case; Darrin M York; Zhuyan Guo
Journal:  J Comput Aided Mol Des       Date:  2016-08-01       Impact factor: 3.686

2.  Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.

Authors:  Shunzhou Wan; Peter V Coveney
Journal:  J R Soc Interface       Date:  2011-01-12       Impact factor: 4.118

3.  Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm.

Authors:  K Marias; D Dionysiou; V Sakkalis; N Graf; R M Bohle; P V Coveney; S Wan; A Folarin; P Büchler; M Reyes; G Clapworthy; E Liu; J Sabczynski; T Bily; A Roniotis; M Tsiknakis; E Kolokotroni; S Giatili; C Veith; E Messe; H Stenzhorn; Yoo-Jin Kim; S Zasada; A N Haidar; C May; S Bauer; T Wang; Y Zhao; M Karasek; R Grewer; A Franz; G Stamatakos
Journal:  Interface Focus       Date:  2011-03-30       Impact factor: 3.906

4.  The performance of ensemble-based free energy protocols in computing binding affinities to ROS1 kinase.

Authors:  Shunzhou Wan; Agastya P Bhati; David W Wright; Alexander D Wade; Gary Tresadern; Herman van Vlijmen; Peter V Coveney
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

5.  T-cell epitope prediction and immune complex simulation using molecular dynamics: state of the art and persisting challenges.

Authors:  Matthew N Davies; Darren R Flower; Kanchan Phadwal; Isabel K Macdonald; Peter V Coveney; Shunzhou Wan
Journal:  Immunome Res       Date:  2010-11-03

6.  Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors.

Authors:  David W Wright; Benjamin A Hall; Owain A Kenway; Shantenu Jha; Peter V Coveney
Journal:  J Chem Theory Comput       Date:  2014-01-27       Impact factor: 6.006

7.  Large scale characterization of the LC13 TCR and HLA-B8 structural landscape in reaction to 172 altered peptide ligands: a molecular dynamics simulation study.

Authors:  Bernhard Knapp; James Dunbar; Charlotte M Deane
Journal:  PLoS Comput Biol       Date:  2014-08-07       Impact factor: 4.475

8.  Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study.

Authors:  Shunzhou Wan; Agastya P Bhati; Stefan J Zasada; Ian Wall; Darren Green; Paul Bamborough; Peter V Coveney
Journal:  J Chem Theory Comput       Date:  2017-01-18       Impact factor: 6.006

9.  The effect of protein mutations on drug binding suggests ensuing personalised drug selection.

Authors:  Shunzhou Wan; Deepak Kumar; Valentin Ilyin; Ussama Al Homsi; Gulab Sher; Alexander Knuth; Peter V Coveney
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors.

Authors:  David W Wright; Benjamin A Hall; Paul Kellam; Peter V Coveney
Journal:  Biology (Basel)       Date:  2012-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.